Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of ZN-c3 in Participants With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04158336
Recruitment Status : Recruiting
First Posted : November 8, 2019
Last Update Posted : February 1, 2023
Sponsor:
Information provided by (Responsible Party):
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Brief Summary:
This is a Phase 1 open-label, multicenter study of ZN-c3 monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: ZN-c3 Phase 1

Detailed Description:

This study will evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN-c3.

In Dose Escalation, the study will identify the Maximum Tolerated Dose (MTD) of ZN-c3 monotherapy in solid tumors.

The Food Effect cohort sub-study will examine ZN-c3 PK after a single dose and determine the bioavailability of ZN-c3 under fed and fasted conditions.

In Dose Expansion, single agent ZN-c3 will be evaluated at the RP2D in subjects with recurrent or persistent uterine serous carcinoma (USC) or subjects with locally advanced or metastatic solid tumor malignancies harboring biomarkers related to deoxyribonucleic acid (DNA) damage pathways.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 146 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: USC Cohort is Parallel Assignment and MOI Cohort is Single Group
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of ZN-c3 as a Single Agent in Subjects With Solid Tumors
Actual Study Start Date : November 1, 2019
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : August 2023

Arm Intervention/treatment
Experimental: Single Agent Dose Escalation
Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
Drug: ZN-c3
ZN-c3 is a study drug
Other Name: Study Drug

Experimental: Single Agent Food Effect Cohort
Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available. This cohort will give subjects the option to continue treatment after PK assessments are completed.
Drug: ZN-c3
ZN-c3 is a study drug
Other Name: Study Drug

Experimental: Single Agent Dose Expansion
Subjects with histologically confirmed recurrent or persistent USC who have had treatment with at least 1 prior platinum-based chemotherapy regimen for management of advanced or metastatic USC and subjects with locally advanced or metastatic malignancy with one or more relevant biomarkers related to DNA damage pathways.
Drug: ZN-c3
ZN-c3 is a study drug
Other Name: Study Drug




Primary Outcome Measures :
  1. Dose Escalation [ Time Frame: Through completion, average of 1 year ]
    To investigate the safety and tolerability of single agent ZN-c3, including identification of the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), based on the incidence and severity of adverse events (AEs) and dose-limiting toxicities (DLTs) in DLT-evaluable subjects.

  2. Food Effect Cohort [ Time Frame: Through completion, approx 6 months ]
    To characterize and compare the PK (Cmax.) of ZN-c3 following a single dose of ZN-c3 under fed and fasting conditions.

  3. Food Effect Cohort [ Time Frame: Through completion, approximately 6 months ]
    To characterize and compare the PK (Tmax) of ZN-c3 following a single dose of ZN-c3 under fed and fasting conditions.

  4. Food Effect Cohort [ Time Frame: Through completion approximately 6 month ]
    To characterize and compare the PK (AUC0-last,AUC0-∞) of ZN-c3 following a single dose of ZN-c3 under fed and fasting conditions.

  5. Food Effect Cohort [ Time Frame: Through completion, approximately 6 mth ]
    To characterize and compare the PK (T1/2) of ZN-c3 following a single dose of ZN-c3 under fed and fasting conditions.

  6. Dose Expansion [ Time Frame: Through completion, approximately 43 month ]
    To investigate the clinical activity of WEE1 inhibition based on the objective response rate (ORR) as defined by the revised Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1


Secondary Outcome Measures :
  1. Dose Escalation, Food Effect cohort & Dose Expansion [ Time Frame: Through completion ]
    To obtain preliminary estimates of antitumor efficacy of single agent ZN-c3 based on objective response rate (ORR) as defined by the revised Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

  2. Food Effect Cohort [ Time Frame: Through completion ]
    To investigate electrocardiogram intervals (QTc Interval) via Holter monitoring after a single dose of ZN-c3 under fed and fasting conditions.

  3. Dose Escalation, Food Effect cohort and Dose Expansion [ Time Frame: Through completion. ]
    To obtain preliminary estimates of antitumor efficacy of single agent ZN-c3 based on Duration of Response (DOR) as defined by the revised Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

  4. Dose Escalation, Food Effect cohort and Dose Expansion [ Time Frame: Through completion.. ]
    To obtain preliminary estimates of antitumor efficacy of single agent ZN-c3 based on Progression Free Survival (PFS) as defined by the revised Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

  5. Dose Escalation, Food Effect cohort and Dose Expansion [ Time Frame: Through completion... ]
    To obtain preliminary estimates of antitumor efficacy of single agent ZN-c3 based on Clinical Benefit Rate (CBR) defined as complete response, partial response or stable disease according to the revised Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Major Eligibility Criteria:

  1. Age ≥ 18 years or the minimum legal adult age (whichever is greater) at the time of informed consent.
  2. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
  3. Adequate hematologic and organ function.
  4. Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception and for 6 months and 90 days, respectively, after the last dose of ZN-c3.

Dose Escalation Inclusion Criteria:

  1. Subjects must have a solid tumor with advanced or metastatic disease, refractory to standard therapy or for whom no standard therapy is available, or the subject is ineligible for standard therapy(ies).
  2. Measurable or evaluable disease per RECIST version 1.1.

Food Effect Cohort Inclusion Criteria:

  1. Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
  2. Subjects must have no relevant dietary restrictions, and be willing to consume a high-calorie, high-fat breakfast and other standard meals provided during the study.

Dose Expansion Inclusion Criteria:

  1. Measurable disease, defined as at least one lesion that can be accurately measured per RECIST version 1.1 criteria.
  2. Recurrent or persistent USC or locally advanced or metastatic malignancy with one or more relevant biomarkers related to deoxyribonucleic acid (DNA) damage pathways.

Major Exclusion Criteria:

  1. Prior therapy with ZN-c3 or known hypersensitivity to any drugs similar to ZN-c3 in class or any inactive ingredients present in ZN-c3.
  2. Prior therapy with a WEE1 inhibitor.
  3. A serious illness or medical condition(s).
  4. Unresolved toxicity of Grade >1 attributed to any prior therapies (excluding Grade ≤2 neuropathy, alopecia or skin pigmentation).
  5. Pregnant or lactating females (including the cessation of lactation) or females of childbearing potential who have a positive serum pregnancy test within 14 days prior to C1D1.
  6. Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.
  7. 12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of >480 ms, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid.
  8. History or current evidence of congenital or family history of long QT syndrome or Torsade de Pointes (TdP).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04158336


Contacts
Layout table for location contacts
Contact: Project Director 858-263-4333 medicalaffairs@zentalis.com

Locations
Layout table for location information
United States, Arizona
Site 0102 Recruiting
Tucson, Arizona, United States, 85719
United States, California
Site 0167 Recruiting
Newport Beach, California, United States, 92663
United States, Illinois
Site 0171 Recruiting
Chicago, Illinois, United States, 60637
United States, Michigan
Site 0101 Recruiting
Detroit, Michigan, United States, 48201
United States, New York
Site 0173 Recruiting
New York, New York, United States, 10029
United States, Pennsylvania
Site 0179 Recruiting
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
Site 0103 Recruiting
Houston, Texas, United States, 77030
Site 0100 Recruiting
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Investigators
Layout table for investigator information
Study Director: Philippe Pultar, MD K-Group Beta, a Zentalis Company
Layout table for additonal information
Responsible Party: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
ClinicalTrials.gov Identifier: NCT04158336    
Other Study ID Numbers: ZN-c3-001
First Posted: November 8, 2019    Key Record Dates
Last Update Posted: February 1, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc:
Uterine Serous Carcinoma
Solid Tumors Harboring Biomarkers Related to DNA Damage Pathways
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms